Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Hematologic Malignancies
Related studies linked through entity extraction aliases.
Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation
- Status
- COMPLETED
- Phase
- NA
Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT)
- Status
- COMPLETED
- Phase
- NA
G-CSF PMRD: Granulocyte Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow and In Vivo T-Cell Depletion in Patients With Hematologic Malignancies or Bone Marrow Failure Syndrome
- Status
- TERMINATED
- Phase
- NA
Allogeneic Bone Marrow Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE2
Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation
- Status
- COMPLETED
- Phase
- PHASE2
Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation
- Status
- COMPLETED
- Phase
- PHASE2
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation
- Status
- COMPLETED
- Phase
- PHASE2
Trial of Prophylactic Versus Empirical Vancomycin for the Prevention of Streptococcal Sepsis After Hematopoietic Cell Transplantation
- Status
- COMPLETED
- Phase
- PHASE3
Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
- Status
- COMPLETED
- Phase
- PHASE2
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies
- Status
- COMPLETED
- Phase
- PHASE2
Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Stem Cell Transplant for Hematologic Diseases
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
IUdR/BUdR Cell Cycle Labelling
- Status
- COMPLETED
- Phase
- NA